NeuroPace (NPCE) Competitors $8.99 +0.37 (+4.29%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$9.04 +0.05 (+0.56%) As of 08/22/2025 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NPCE vs. BLFS, MDXG, ESTA, PLSE, INMD, IRMD, TNDM, KMTS, EMBC, and SIBNShould you be buying NeuroPace stock or one of its competitors? The main competitors of NeuroPace include BioLife Solutions (BLFS), MiMedx Group (MDXG), Establishment Labs (ESTA), Pulse Biosciences (PLSE), InMode (INMD), iRadimed (IRMD), Tandem Diabetes Care (TNDM), Kestra Medical Technologies (KMTS), Embecta (EMBC), and SiBone (SIBN). These companies are all part of the "medical equipment" industry. NeuroPace vs. Its Competitors BioLife Solutions MiMedx Group Establishment Labs Pulse Biosciences InMode iRadimed Tandem Diabetes Care Kestra Medical Technologies Embecta SiBone NeuroPace (NASDAQ:NPCE) and BioLife Solutions (NASDAQ:BLFS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability and institutional ownership. Which has preferable valuation & earnings, NPCE or BLFS? BioLife Solutions has lower revenue, but higher earnings than NeuroPace. BioLife Solutions is trading at a lower price-to-earnings ratio than NeuroPace, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeuroPace$88.57M3.36-$27.14M-$0.84-10.70BioLife Solutions$82.25M15.09-$20.18M-$0.12-215.92 Do institutionals & insiders hold more shares of NPCE or BLFS? 78.8% of NeuroPace shares are held by institutional investors. Comparatively, 93.2% of BioLife Solutions shares are held by institutional investors. 20.5% of NeuroPace shares are held by company insiders. Comparatively, 2.2% of BioLife Solutions shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more risk and volatility, NPCE or BLFS? NeuroPace has a beta of 1.89, indicating that its share price is 89% more volatile than the S&P 500. Comparatively, BioLife Solutions has a beta of 1.76, indicating that its share price is 76% more volatile than the S&P 500. Does the media prefer NPCE or BLFS? In the previous week, NeuroPace had 6 more articles in the media than BioLife Solutions. MarketBeat recorded 14 mentions for NeuroPace and 8 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 1.39 beat NeuroPace's score of 0.84 indicating that BioLife Solutions is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroPace 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioLife Solutions 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate NPCE or BLFS? NeuroPace currently has a consensus price target of $16.60, suggesting a potential upside of 84.65%. BioLife Solutions has a consensus price target of $31.29, suggesting a potential upside of 20.75%. Given NeuroPace's higher probable upside, research analysts plainly believe NeuroPace is more favorable than BioLife Solutions.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NeuroPace 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83BioLife Solutions 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Is NPCE or BLFS more profitable? BioLife Solutions has a net margin of -5.39% compared to NeuroPace's net margin of -29.29%. BioLife Solutions' return on equity of 0.16% beat NeuroPace's return on equity.Company Net Margins Return on Equity Return on Assets NeuroPace-29.29% -168.61% -25.48% BioLife Solutions -5.39%0.16%0.14% SummaryBioLife Solutions beats NeuroPace on 11 of the 17 factors compared between the two stocks. Get NeuroPace News Delivered to You Automatically Sign up to receive the latest news and ratings for NPCE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NPCE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NPCE vs. The Competition Export to ExcelMetricNeuroPaceMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$297.40M$6.82B$5.75B$9.62BDividend YieldN/A1.31%4.40%4.10%P/E Ratio-10.7027.4531.3026.05Price / Sales3.3674.72432.98193.75Price / CashN/A21.3437.7358.48Price / Book15.246.889.536.61Net Income-$27.14M$176.42M$3.26B$265.65M7 Day Performance5.02%1.45%2.13%2.02%1 Month Performance-5.37%-2.71%2.80%-0.31%1 Year Performance13.51%9.40%30.68%19.06% NeuroPace Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NPCENeuroPace3.4796 of 5 stars$8.99+4.3%$16.60+84.6%+28.2%$297.40M$88.57M-10.70170Short Interest ↑BLFSBioLife Solutions2.688 of 5 stars$22.37-1.4%$31.29+39.9%+6.0%$1.09B$82.25M-186.40440News CoverageInsider TradeHigh Trading VolumeMDXGMiMedx Group3.243 of 5 stars$7.04+0.3%$12.00+70.5%+11.1%$1.04B$348.88M33.53870ESTAEstablishment Labs1.9133 of 5 stars$33.63-3.4%$55.80+65.9%+0.7%$1.01B$166.02M-11.031,018News CoverageAnalyst ForecastHigh Trading VolumePLSEPulse Biosciences3.4989 of 5 stars$14.88+1.2%$22.00+47.8%-20.8%$989.60M$700K0.00140INMDInMode1.9668 of 5 stars$13.80-2.2%$18.04+30.7%-4.4%$891.88M$394.82M5.59480Positive NewsIRMDiRadimed4.637 of 5 stars$70.00+0.1%$72.00+2.9%+62.5%$889.51M$73.24M43.21110Positive NewsTNDMTandem Diabetes Care4.6554 of 5 stars$10.11-10.0%$22.67+124.2%-71.9%$758.80M$940.20M-3.272,650Positive NewsAnalyst ForecastKMTSKestra Medical TechnologiesN/A$14.65+0.9%$27.33+86.6%N/A$745.58M$59.81M0.00300News CoverageEMBCEmbecta4.8379 of 5 stars$12.73+3.7%$19.00+49.3%+9.0%$717.67M$1.12B8.902,100Positive NewsHigh Trading VolumeSIBNSiBone4.1725 of 5 stars$15.40-1.8%$23.67+53.7%+10.0%$676.45M$167.18M-27.50350News CoverageInsider Trade Related Companies and Tools Related Companies BioLife Solutions Alternatives MiMedx Group Alternatives Establishment Labs Alternatives Pulse Biosciences Alternatives InMode Alternatives iRadimed Alternatives Tandem Diabetes Care Alternatives Kestra Medical Technologies Alternatives Embecta Alternatives SiBone Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NPCE) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroPace, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroPace With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access